Our dedication to advancing women in the legal profession extends beyond the firm. Axinn attorneys will be speaking at the ACI 13th Annual Summit for Women Leaders in Life Sciences Law in Boston from July 29-30. The Annual Summit is an event dedicated to fostering collaboration, networking, and professional development among more than 300 attorneys and executives from the biotech, pharmaceutical, and medical device industries. It offers an important forum to exchange insights on the latest legal developments and industry challenges.
47% of Axinn Attorneys Are Women:
58%
of Associates
35%
of Partners and Counsel
54%
of The Firm’s Leadership
43%
of the Incoming Fall Class
Notable Recognitions
Axinn Speakers at the Conference
On July 29, Rebecca will speak on “Breaking Down the Latest Disputes in mRNA, LNP, and ADC Patents.”
Panelists will break down the latest litigation trends and what they mean for protecting and advancing cutting-edge therapies.
On July 30, Denise will speak on “Life Sciences on Trial: Breaking Down the Top 10 Court Cases Impacting the Life Sciences Industry in 2026.”
Panelists will examine the cases making the biggest impact and discuss how these rulings are shaping the next wave of litigation and regulatory risk.
Why Leading Life Sciences Companies Turn to Axinn
- Vast knowledge and understanding of the development, approval pathways, and monetization of life science products, allowing us to achieve a client’s business goals in the face of major obstacles
- Well-established patent litigation firm with significant trial experience in controversies involving pharmaceutical, medical device, and life science patents
- Counseling services, pre-litigation strategies, and advice on the benefits of filing IPR petitions to assist clients in the selection, development, approval, and marketing of a broad range of technologies and therapies
- Unmatched depth in the skills needed to address health care collaboration and competition. We represent companies across the health care universe, including providers, payors, suppliers and distributors, technology companies, and investors
Our Life Sciences and Biotechnology Experience
- Represented Johnson & Johnson’s Synthes in a patent infringement case involving spinal implant technology filed against Globus Medical in the District of Delaware, concluding in a complete trial victory and $16M+ jury award
- Represented Actavis in an eight-year battle over the multi-billion-dollar drug Neurontin, after remand from the Federal Circuit and after Actavis’s at-risk launch. We impeached plaintiff Pfizer’s witnesses at trial and excluded key expert testimony. The case settled on very favorable terms after two weeks of trial
- Represented Natco in a successful appeal on behalf of a generic version of Tamiflu, obtaining a reversal of the trial court’s holding that a later-issued but earlier-expiring patent cannot serve as a double-patenting reference against an earlier-issued but later-expiring patent
- Defended McKesson’s RelayHealth in an FTC investigation and litigation, as well as a treble-damages follow-on class action alleging conspiracy to monopolize. Secured an advantageous early resolution
- Defended Alvogen in multiple treble-damage class action suits alleging an industry-wide conspiracy to raise prices of generic medications through the allocation of markets
Featured Viewpoints
Featured Viewpoints
What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions
No More Needles in Haystacks: Congress Requires FDA to Explain Q1/Q2 Sameness
Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed
The Skinny on Infringement of Method of Treatment Claims
My Prescription Costs What?
FTC Throws Down the Gauntlet on Improper Orange Book Listings
Who’s Blocking Me? Competition Law Issues With Healthcare Information Blocking
Podcast
